Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) shot up 3% during trading on Wednesday . The company traded as high as $7.20 and last traded at $6.88. 1,947,322 shares changed hands during trading, an increase of 20% from the average session volume of 1,623,936 shares. The stock had previously closed at $6.68.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Monday, April 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $10.50.
View Our Latest Stock Report on Tango Therapeutics
Tango Therapeutics Stock Up 1.0%
The business's fifty day moving average is $4.55 and its 200-day moving average is $2.90. The stock has a market capitalization of $739.22 million, a PE ratio of -5.59 and a beta of 1.63.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 322.67% and a negative return on equity of 62.75%. The company had revenue of $5.39 million during the quarter, compared to analysts' expectations of $6.73 million. As a group, sell-side analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Tango Therapeutics
Several institutional investors have recently bought and sold shares of the business. CWM LLC lifted its position in shares of Tango Therapeutics by 182.2% during the second quarter. CWM LLC now owns 4,905 shares of the company's stock worth $25,000 after purchasing an additional 3,167 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Tango Therapeutics in the fourth quarter valued at $33,000. Stonebrook Private Inc. acquired a new stake in Tango Therapeutics in the fourth quarter valued at $34,000. Ameriprise Financial Inc. acquired a new stake in Tango Therapeutics in the fourth quarter valued at $35,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Tango Therapeutics during the fourth quarter worth $38,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
